Cannabidiol ameliorates cognitive function via regulation of IL-33 and TREM2 upregulation in a murine model of Alzheimer's Disease

Hesam Khodadadi, Évila Lopes Salles, Abbas Jarrahi, Vincenzo Costigliola, M. B. Khan, Jack C. Yu, John C. Morgan, David C. Hess, Kumar Vaibhav, Krishnan M. Dhandapani, Babak Baban

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

There is a dire need for due innovative therapeutic modalities to improve outcomes of AD patients. In this study, we tested whether cannabidiol (CBD) improves outcomes in a translational model of familial AD and to investigate if CBD regulates interleukin (IL)-33 and triggering receptor expressed on myeloid cells 2 (TREM2), which are associated with improved cognitive function. CBD was administered to 5xFAD mice, which recapitulate early onset, familial AD. Behavioral tests and immunoassays were used to evaluate cognitive and motor outcomes. Our findings suggest that CBD treatment enhanced IL-33 and TREM2 expression, ameliorated the symptoms of AD, and retarded cognitive decline.

Original languageEnglish (US)
Pages (from-to)973-977
Number of pages5
JournalJournal of Alzheimer's Disease
Volume80
Issue number3
DOIs
StatePublished - 2021

Keywords

  • Alzheimer's disease
  • CBD
  • Cannabidiol
  • Dementia
  • ILC2
  • Innate lymphoid cells

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Cannabidiol ameliorates cognitive function via regulation of IL-33 and TREM2 upregulation in a murine model of Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this